GSK files supplementary NDA for asthma treatment arnuity ellipta
GSK has submitted a supplementary new drug application (sNDA) to the US Food and Drug Administration (FDA) for the use of arnuity ellipta (fluticasone furoate) as a maintenance treatment of children with asthma.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Asthma | Children | Flonase | Food and Drug Administration (FDA) | New Drug Applications | Pharmaceuticals